Z Squared Inc. (ZSQR) company profile
Close on Nov 18, 2026Market cap $115.81MP/E –Yield –
About Z Squared
Finance Services, SIC 6199
Coeptis Therapeutics Holdings, Inc. operates as a biopharmaceutical and technology company structured across two main divisions. Its biopharmaceutical division develops cell therapy platforms, including natural killer cell therapies, chimeric antigen receptor technologies, and diagnostic tools designed for cancer, autoimmune conditions, and infectious diseases. Its technology division provides artificial intelligence marketing software and robotic process automation tools to optimize enterprise workflows. The company directs its healthcare solutions toward patients suffering from hematologic malignancies and viral infections, while its technology services cater to corporate clients seeking advertising campaigns and digital webinar solutions.
The company is headquartered in Wexford, Pennsylvania, and operates as a Delaware corporation following its initial incorporation in the British Virgin Islands. Business activities are conducted through several operating subsidiaries, including majority-owned SNAP Biosciences and GEAR Therapeutics, as well as wholly owned pharmaceutical units. Its clinical development pipeline includes two Phase 1 trial programs.
Summary of the business section of Z Squared's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Z Squared Inc.
- Founded
- 2018
- Headquarters
- Fort Lauderdale, FL
- Address
- 550 South Andrews Ave., Ste #700 33301
- Phone
- (954) 400-9994
- Website
- zsquaredinc.com
- Employees
- 6, Dec 31, 2025
- Industry
- Finance Services
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Astra Audit and Advisory LLC, Tampa, Florida
Stock & identifiers
- Ticker
- ZSQR
- Former tickers
- COEP until Apr 28, 2026; BHSE until Nov 3, 2022
- Exchange
- Nasdaq
- IPO date
- Nov 2, 2020
- Shares outstanding
- 53M, Aug 11, 2026
- Public float
- $28.23M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 13-for-1, Aug 13, 2026; 1-for-20 reverse, Dec 31, 2024
- SEC CIK
- 1759186
- CUSIP
- 98878K108
- ISIN
- US98878K1088
- FIGI
- BBG00XTTT1C5
- Share class FIGI
- BBG00XTTT1D4
- LEI
- 5299004UXP8XTVR4KR35
- EIN
- 98-1465952
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Elias Halabu | Chief Executive Officer, Director | 1,464,905 |
| Michelle Ellen Burke | Co-Chief Executive Officer, Director | 16,447 |
| Daniel Alexander Yerace | VP Operations, Director | 70,531 |
| David Mehalick | CEO and President, Director | 330,192 |
| Christopher Ryan Schadel | Chief Marketing Officer | 6,636 |
| Brian Cogley | Chief Financial Officer | 30,724 |
| Jeffery Keeslar Harris | Chief Technology Officer | 12,444 |
| Christine Elise Sheehy | VP Compliance and Secy | 64,031 |
| Kenneth Lyle Cooper | Director | 1,644 |
| Bryan Eric Fuerst | Director | 1,644 |
| Adam Craig Sohn | Director | 1,644 |
| Gene Salkind | Director | 41,799 |
| Christopher P. Cochran | Director | 8,950 |
| Tara DeSilva | Director | 8,950 |
| Chris Calise | Director | 2,243,741 |
| Philippe Deschamps | Director | 8,950 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Nov 2, 2020
- Offer price
- $10.00
- Securities offered
- 7,500,000
- Gross proceeds
- $75.00M
- Exchange
- Nasdaq
- First trading day
- Dec 17, 2020
- First-day close
- $9.90-1.0%
- Lock-up ends (est.)
- Jun 15, 2021
“We are offering 7,500,000 units at an offering price of $10.00 per unit.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“Currently, we have six employees, of which four are full-time employees and two are part-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?